Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus TQB2450 first-line treatment study in advanced esophageal squamous cell carcinoma
ChiCTR2500102140Phase 2Not yet recruiting
- Sponsor
- Zhenjiang First People's Hospital
- Start
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib and benmelstobart in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhenjiang First People's Hospital. Planned start May 2025; status: not yet recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500102140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102140.